Press Releases
- Results from tasquinimod study in heavily pretreated patients with relapsed refractory multiple myeloma presented at ASCO 2025 available on Active Biotech’s website
- Annual General Meeting of Active Biotech AB
- Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma
- Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe
- Active Biotech Interim Report Q1 2025